-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Citius Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q4 2010 to Q2 2024.
- Citius Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $144K, unchanged year-over-year.
- Citius Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $576K.
- Citius Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $576K, unchanged from 2022.
- Citius Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $576K, a 46615% increase from 2021.
- Citius Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $1.23K, a 66.4% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)